ovarian cancer clinical trials results

niraparib versus placebo
ENGOT-OV16/NOVA,
NCT01847274
niraparib (300 mg) once daily
versus
placebo
patients with platinum-sensitive, recurrent ovarian cancerdouble-blind
olaparib versus placebo
SOLO2/ENGOT-Ov21 ,
NCT01874353
olaparib 300 mg in two 150 mg tablets, twice daily
versus
placebo
patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutationdouble-blind
international
olaparid versus placebo
Ledermann, 2012
NCT00753545
olaparib, at a dose of 400 mg twice daily
versus
placebo
patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen